NAD+ IV infusion

The evidence base does not support the healthspan claims made for it. There is no human randomised controlled trial showing any longevity, healthspan or biological-ageing outcome from IV NAD+. The most relevant retrieved human data is a retrospective real-world pilot (PMC12907335) comparing IV NAD+ with IV nicotinamide riboside: it enrolled only 6 NAD+ recipients versus 8 NR recipients, was uncontrolled and unblinded, and was authored by staff of the commercial clinic delivering the treatment. It assessed tolerability and 30-day safety only, explicitly not efficacy. Notably, its findings cut against the marketing: the NAD+ arm reported moderate to severe abdominal cramping, diarrhoea, nausea, vomiting and chest pressure, while NR caused only minor tingling, and NAD+ infusions took 97 minutes versus 37. Metabolic readouts were exploratory only, and the authors could not even detect NAD+ concentration changes. The rationale for the intervention therefore rests on mechanism and on rodent work, not on demonstrated human outcomes. A candid signal: Artisan Regenerative's own service page describes NAD+ IV as "an unrecognized medical drug" and concedes limited clinical trial data, while simultaneously listing benefit claims spanning cognition, immunity, cardiovascular, liver, kidney and muscle function. REGULATORY, IMPORTANT LIMITATION: neither market's status was verified and both are returned as null rather than guessed. The TGA website timed out on four separate fetch attempts, so a safety alert that search results indicate exists at tga.gov.au titled "NAD, NAD+, NADH or NMN medicines sold in Australia" could not be opened or quoted; it is the single highest-priority follow-up and should be retrieved before any regulatory claim is published. No HSA source was successfully opened either. Search-result summaries suggested that NAD/NAD+/NADH are not permitted ingredients in Australian listed medicines and that Singapore restricts IV therapy outside licensed healthcare institutions, but both are secondhand search-engine paraphrases of non-authoritative pages and are deliberately excluded here. CLINICS: only Artisan Regenerative Centre is confirmed from its own site. Australian Longevity Clinic's homepage returned no service detail on fetch, so it is not listed despite the discovery note. Biogenix Australia was confirmed offering "NAD+ Therapy" from its own site but is not on the supplied AU clinic list, so it is excluded from offeredBy while still evidencing genuine AU availability.

What it is

Plain-language explainer

Categories

Common questions

What is NAD+ IV infusion?

The evidence base does not support the healthspan claims made for it. There is no human randomised controlled trial showing any longevity, healthspan or biological-ageing outcome from IV NAD+. The most relevant retrieved human data is a retrospective real-world pilot (PMC12907335) comparing IV NAD+ with IV nicotinamide riboside: it enrolled only 6 NAD+ recipients versus 8 NR recipients, was uncontrolled and unblinded, and was authored by staff of the commercial clinic delivering the treatment. It assessed tolerability and 30-day safety only, explicitly not efficacy. Notably, its findings cut against the marketing: the NAD+ arm reported moderate to severe abdominal cramping, diarrhoea, nausea, vomiting and chest pressure, while NR caused only minor tingling, and NAD+ infusions took 97 minutes versus 37. Metabolic readouts were exploratory only, and the authors could not even detect NAD+ concentration changes. The rationale for the intervention therefore rests on mechanism and on rodent work, not on demonstrated human outcomes. A candid signal: Artisan Regenerative's own service page describes NAD+ IV as "an unrecognized medical drug" and concedes limited clinical trial data, while simultaneously listing benefit claims spanning cognition, immunity, cardiovascular, liver, kidney and muscle function. REGULATORY, IMPORTANT LIMITATION: neither market's status was verified and both are returned as null rather than guessed. The TGA website timed out on four separate fetch attempts, so a safety alert that search results indicate exists at tga.gov.au titled "NAD, NAD+, NADH or NMN medicines sold in Australia" could not be opened or quoted; it is the single highest-priority follow-up and should be retrieved before any regulatory claim is published. No HSA source was successfully opened either. Search-result summaries suggested that NAD/NAD+/NADH are not permitted ingredients in Australian listed medicines and that Singapore restricts IV therapy outside licensed healthcare institutions, but both are secondhand search-engine paraphrases of non-authoritative pages and are deliberately excluded here. CLINICS: only Artisan Regenerative Centre is confirmed from its own site. Australian Longevity Clinic's homepage returned no service detail on fetch, so it is not listed despite the discovery note. Biogenix Australia was confirmed offering "NAD+ Therapy" from its own site but is not on the supplied AU clinic list, so it is excluded from offeredBy while still evidencing genuine AU availability.

How strong is the evidence for NAD+ IV infusion?

Commercial. It is offered and sold, which is a statement about availability, not about efficacy.

Is NAD+ IV infusion approved in Singapore?

variis has no Health Sciences Authority position on file for NAD+ IV infusion. Absence of a recorded position is not approval.

Is NAD+ IV infusion approved in Australia?

variis has no Therapeutic Goods Administration position on file for NAD+ IV infusion. Absence of a recorded position is not approval.

Which clinics offer NAD+ IV infusion?

1 clinic in the variis directory across Singapore and Australia has NAD+ IV infusion on record. Each is listed on this page with its own sourced profile.

What else is NAD+ IV infusion called?

Also known as NAD+ drip, intravenous nicotinamide adenine dinucleotide, NAD IV therapy, IV NAD+.